Therapeutics News and Research

RSS

Drinking extra 2 cups of coffee per day may reduce cirrhosis risk by 44%

Regular consumption of coffee was linked with a reduced risk of liver cirrhosis in a review of relevant studies published before July 2015.

1 Feb 2016

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer.

1 Feb 2016

Newcastle University scientists use seaweed extract to develop 'Stem-gell' bandage for wound healing

Publishing in STEM CELLS Translational Medicine Professor Che Connon and Dr Stephen Swioklo describe the low-cost seaweed solution.

1 Feb 2016

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.

30 Jan 2016

ProteinSimple expands Simple Plex immunoassay offering with launch of new single analyte cartridge

ProteinSimple announced today an expansion of the Simple Plex immunoassay offering by launching a new single analyte cartridge for the analysis of 72 samples at once. This new cartridge enables Simple Plex users to run 72 samples in an hour with triplicate results. It is powered by R&D Systems reagents, the expert in immunoassays.

From ProteinSimple 29 Jan 2016

Brain's natural plasticity could compensate for inner ear damage

Researchers from Massachusetts Eye and Ear/Harvard Medical School have described, for the first time, the adult brain's ability to compensate for a near-complete loss of auditory nerve fibers that link the ear to the brain. The findings, published in the current issue of Neuron, suggest that the brain's natural plasticity can compensate for inner ear damage to bring sound detection abilities back within normal limits; however, it does not recover speech intelligibility.

29 Jan 2016

Researchers discover potential candidates for development of novel targeted therapies for blood cancers

A research team from the Department of Pharmacology and Therapeutics at Roswell Park Cancer Institute has discovered a new class of small-molecule compounds that are good candidates for development of novel targeted therapies in the treatment of leukemia and lymphoma.

28 Jan 2016

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Leaders of several cancer centers designated by the National Cancer Institute have united to support human papillomavirus vaccination. Among them is Cheryl Willman, MD, Director and CEO of the University of New Mexico Comprehensive Cancer Center.

28 Jan 2016

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Building upon more than two decades of basic research conducted at Children's Hospital Los Angeles, Araz Marachelian, MD, of CHLA, and her colleagues at pediatric academic centers across the U. S., have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients.

28 Jan 2016

Halozyme closes $150 million royalty-backed debt transaction

Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta.

27 Jan 2016

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan.

22 Jan 2016

Dartmouth researchers discover rare natural products that promote regeneration of injured nerve cells

Nerve damage from neurodegenerative disease and spinal cord injury has largely been considered irreversible, but Dartmouth researchers report progress in the effort to synthesize rare natural products that promote regeneration and growth of injured nerve cells.

22 Jan 2016

New machine-learning technique could be used to uncover previously unknown features of organisms

A powerful new machine-learning technique can be applied to large datasets in the biological sciences to uncover previously unknown features of organisms and their genes, according to a team led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

22 Jan 2016

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.

21 Jan 2016

Gene therapy holds considerable potential for safe, effective treatment of people with factor VII deficiency

Hematology researchers have used a single injection of gene therapy to correct a rare bleeding disorder, factor VII deficiency, in dogs. This success in large animals holds considerable potential for a safe, effective and long-lasting new treatment in humans with the same bleeding disorder.

21 Jan 2016

CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

Colorado State University's Biopharmaceutical Manufacturing and Academic Resource Center has been awarded a 10-month, $4.6 million contract funded by the Department of Defense to help develop and manufacture new vaccines to fight encephalitic viruses that cause inflammation of the brain.

21 Jan 2016

Upsher-Smith, Saniona sign drug discovery and development agreement

Upsher-Smith Laboratories, Inc., through its wholly-owned subsidiary Proximagen Ltd., and Saniona, a leading biotech company in the field of ion channels, today announce that they have entered into a drug discovery and development collaboration.

20 Jan 2016

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

A $15.7 million grant from the Atlanta-based Marcus Foundation has helped launch a new Georgia Institute of Technology research center that will develop processes and techniques for ensuring the consistent, low-cost, large-scale manufacture of high-quality living cells used in cell-based therapies.

20 Jan 2016

Artificial pancreas moves closer to becoming a reality

As the accuracy, reliability, adoption, and successful use of Continuous Glucose Monitoring (CGM) continue to increase, the ultimate goal of combining CGM with an insulin pump and sophisticated algorithms for automating the control and suspension of insulin infusion--known as the "artificial pancreas"--moves closer to becoming a reality.

20 Jan 2016

Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

A nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumors while decreasing toxicity.

20 Jan 2016

Therapeutics News and Research

Drinking extra 2 cups of coffee per day may reduce cirrhosis risk by 44%

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

Newcastle University scientists use seaweed extract to develop 'Stem-gell' bandage for wound healing

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

ProteinSimple expands Simple Plex immunoassay offering with launch of new single analyte cartridge

Brain's natural plasticity could compensate for inner ear damage

Researchers discover potential candidates for development of novel targeted therapies for blood cancers

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Halozyme closes $150 million royalty-backed debt transaction

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Dartmouth researchers discover rare natural products that promote regeneration of injured nerve cells

New machine-learning technique could be used to uncover previously unknown features of organisms

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Gene therapy holds considerable potential for safe, effective treatment of people with factor VII deficiency

CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

Upsher-Smith, Saniona sign drug discovery and development agreement

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

Artificial pancreas moves closer to becoming a reality

Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

Next-generation therapeutics eBook eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News